- Home
- IFBD vs MYNZ Comparison
IFBD vs MYNZ Comparison
Compare IFBD & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFBD
- MYNZ
- Stock Information
- Founded
- IFBD 2001
- MYNZ 2021
- Country
- IFBD China
- MYNZ Germany
- Employees
- IFBD N/A
- MYNZ N/A
- Industry
- IFBD Computer Software: Prepackaged Software
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- IFBD Technology
- MYNZ Health Care
- Exchange
- IFBD Nasdaq
- MYNZ Nasdaq
- Market Cap
- IFBD 8.4M
- MYNZ 7.9M
- IPO Year
- IFBD 2021
- MYNZ 2021
- Fundamental
- Price
- IFBD $1.20
- MYNZ $1.53
- Analyst Decision
- IFBD
- MYNZ Buy
- Analyst Count
- IFBD 0
- MYNZ 2
- Target Price
- IFBD N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- IFBD 459.9K
- MYNZ 534.4K
- Earning Date
- IFBD 05-01-2023
- MYNZ 12-29-2025
- Dividend Yield
- IFBD N/A
- MYNZ N/A
- EPS Growth
- IFBD N/A
- MYNZ N/A
- EPS
- IFBD N/A
- MYNZ N/A
- Revenue
- IFBD $4,861,442.00
- MYNZ $659,935.00
- Revenue This Year
- IFBD N/A
- MYNZ $26.06
- Revenue Next Year
- IFBD N/A
- MYNZ $4.97
- P/E Ratio
- IFBD N/A
- MYNZ N/A
- Revenue Growth
- IFBD 1520.48
- MYNZ N/A
- 52 Week Low
- IFBD $0.89
- MYNZ $1.28
- 52 Week High
- IFBD $3.32
- MYNZ $14.39
- Technical
- Relative Strength Index (RSI)
- IFBD 58.37
- MYNZ 46.59
- Support Level
- IFBD $1.12
- MYNZ $1.51
- Resistance Level
- IFBD $1.23
- MYNZ $1.63
- Average True Range (ATR)
- IFBD 0.09
- MYNZ 0.11
- MACD
- IFBD 0.01
- MYNZ 0.01
- Stochastic Oscillator
- IFBD 51.35
- MYNZ 51.61
About IFBD Infobird Co. Ltd
Infobird Co Ltd is engaged in developing and providing customer engagement cloud-based services. It software-as-a-service provider of AI-powered, or artificial intelligence-enabled, customer engagement solutions in China. It provides holistic software solutions to help corporate clients proactively deliver and manage end-to-end customer engagement activities at all stages of the sales process, including pre-sales and sales activities, and post-sales customer support. It also offers AI-powered cloud-based sales force management software, including intelligent quality inspection and intelligent training software to help clients monitor, benchmark, and improve the performance of agents.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.